Xinnaoxin Tablet Pharmacology Study on High-Altitude Cardiac Injury

Zhihui Wang published a pharmacological study on figshare in 2026. The research investigates the mechanisms of Xinnaoxin tablets in ameliorating high-altitude polycythemia-associated cardiac injury using a mouse model. The dataset likely contains detailed experimental results from systems pharmacology and multi-level analyses.

Use Cases

• Analyzing drug efficacy on blood parameters based on red blood cell count, hemoglobin, hematocrit, and plasma viscosity measurements.
• Studying cardioprotective effects based on histopathology, echocardiography, and oxidative stress indicators.
• Investigating signaling pathway modulation based on phosphorylation status of MAPK, JNK, ERK, IκBα, NF-κB, and Akt.
• Evaluating bone marrow erythropoietic efficiency based on the proportion and apoptosis of CD71+ cells.

Strengths

• The study employs a combined strategy of systems pharmacology and multi-level analysis.
• Experimental assessments include complete blood parameters, hemorheology, histopathology, echocardiography, and Western blot analyses.
• The dataset is openly licensed under CC-BY-4.0.

Limitations

• The dataset is a 51.4 KB PDF file, indicating limited scope and likely containing summary results rather than raw data.
• Column-level documentation is absent; field semantics must be inferred from the text.
• Row count is unknown, which may limit suitability assessment for quantitative analysis.

Provenance

Source

figshare

Collection Method

Experimental study using a hypobaric hypoxia mouse model and UPLC-Q-TOF-MS analysis.

Freshness

Last updated 2026-05-28 04:53:02; freshness should be verified.